Completed PHASE4 INTERVENTIONAL 3-arm NCT00350701

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism

Sponsor: Solvay Pharmaceuticals

Interventions androgel androgel 10g placebo

Updated 9 times since 2017 Last updated: Jan 14, 2022 Started: Jul 31, 2006 Primary completion: Jun 30, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Diabetes Mellitus Type 2, this trial is completed. The trial is conducted by Solvay Pharmaceuticals and has accumulated 9 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Mar 2022 — Dec 2022 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 4 earlier versions

Jan 2021 — Mar 2022 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE4
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Solvay Pharmaceuticals
University at Buffalo

Data source: University at Buffalo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States